Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Haoyuan Chemexpress Co's quarterly market cap
declined
from Sep. 2025 (¥17,519 Mil) to Dec. 2025 (¥15,288 Mil) and
declined
from Dec. 2025 (¥15,288 Mil) to Mar. 2026 (¥14,701 Mil).
Shanghai Haoyuan Chemexpress Co's annual market cap
declined
from Dec. 2023 (¥7,829 Mil) to Dec. 2024 (¥7,530 Mil) but then
increased
from Dec. 2024 (¥7,530 Mil) to Dec. 2025 (¥15,288 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Shanghai Haoyuan Chemexpress Co's Enterprise Value for Today is ¥16,343 Mil.
Shanghai Haoyuan Chemexpress Co (SHSE:688131) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Shanghai Haoyuan Chemexpress Co Market Cap Related Terms
Shanghai Haoyuan Chemexpress Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Haoyuan Chemexpress Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Haoyuan Chemexpress Co Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shanghai Haoyuan Chemexpress Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Shanghai Haoyuan Chemexpress Co's Market Cap falls into.
Shanghai Haoyuan Chemexpress Co Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Haoyuan Chemexpress Co (SHSE:688131) has a Market Cap of ¥15,204 Mil as of Jul. 22, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Shanghai Haoyuan Chemexpress Co and its competitors. According to the industry distribution chart, Shanghai Haoyuan Chemexpress Co ranks #144 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 14.1%.
Is Shanghai Haoyuan Chemexpress Co's Market Cap too high?
Shanghai Haoyuan Chemexpress Co's current Market Cap is ¥15,204 Mil. Based on the distribution chart, Shanghai Haoyuan Chemexpress Co ranks #144 out of 1022 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Haoyuan Chemexpress Co has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haoyuan Chemexpress Co's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shanghai Haoyuan Chemexpress Co ranks #144 out of 1022 companies for Market Cap. This places Shanghai Haoyuan Chemexpress Co in the top 14% of its industry — outperforming the majority of peers. The industry median Market Cap is 215.88. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 215.88, based on 1,022 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Shanghai Haoyuan Chemexpress Co and its competitors. For the Drug Manufacturers industry, the median Market Cap is 215.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Haoyuan Chemexpress Co's current Market Cap is ¥15,204 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haoyuan Chemexpress Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Haoyuan Chemexpress Co (SHSE:688131) is currently considered Fairly Valued. The stock's GF Value™ is ¥65.89, compared to a current price of ¥71.30 — trading 8.2% above its estimated fair value. The current Market Cap is ¥15,204 Mil. Shanghai Haoyuan Chemexpress Co's overall GF Score™ is 92/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Shanghai Haoyuan Chemexpress Co (SHSE:688131), the current Market Cap is ¥15,204 Mil as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Haoyuan Chemexpress Co (SHSE:688131) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Haoyuan Chemexpress Co stock appears to be overvalued.
The current stock price of ¥71.30 is trading 8.2% above its estimated GF Value™ of ¥65.89.
GuruFocus considers Shanghai Haoyuan Chemexpress Co to be Fairly Valued.
Key valuation signals for SHSE:688131:
Market Cap: ¥15,204 Mil
GF Value™: ¥65.89 vs. price of ¥71.30 (8.2% above fair value)
No single metric tells the full story. See the SHSE:688131 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Haoyuan Chemexpress Co Business Description
Shanghai Haoyuan Chemexpress Co Ltd focuses on providing small molecule and new modalities CDMO services for both pharmaceutical and biotech clients. The company's comprehensive CRO & CDMO platform is engaged in the research and development, manufacturing and supply of regulatory starting materials, novel building blocks, intermediates, reference compounds, APIs and drug products. It is a one-stop service platform to support client's projects from early drug discovery, process development to commercialization. The company is committed to delivering high-quality products and CMC services to clients across the entire life cycle of drug development.
92GF Score
Get the complete analysis for SHSE:688131
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688131 has been successfully added to your 
